Encouraging Results with Obinutuzumab for Lupus Nephritis
February 13, 2022
The LRA is pleased to share a recently published paper reporting that the drug, obinutuzumab, showed positive...
Dr. Richard Furie
Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca’s anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)
First in New Class of Drugs in More than a Decade for SLE Targeting Type 1 Interferons
NEW YORK, NY....
Breadth of Clinical Research Presented at the 2019 ACR/ARP Annual Meeting Brings Hope for New Lupus Treatments
November 14, 2019
The Lupus Research Alliance staff was on the ground at the 2019 ACR/ARP Annual Meeting and highly...
Positive Early Results for BIIB059 as New Treatment Strategy
February 28, 2019
Proteins of the immune system, known as type I interferons, are responsible in part for manifestations of...